| AF | |||||
|---|---|---|---|---|---|
| Apixaban (n = 103) |
Rivaroxaban (n = 174) |
Apixaban and rivaroxaban combined (n = 277) |
Warfarin (n = 152) |
Total (n = 429) |
|
| Age at the time of prescription (years) |
65.9 (10.7) | 60.9 (12.6) | 62.7 (12.1)* | 66.8 (13.6) | 64.2 (12.8) |
| BMI (kg/m²) | 43.8 (41.0-48.1) |
44.6 (41.8-48.6) |
44.4 (41.5-48.3) |
44.5 (41.7-52.3) |
44.4 (41.6-49.4) |
| ≥50 | 19 (18%) | 37 (21%) | 56 (20%)* | 44 (29%) | 100 (23%) |
| Female | 58 (56%) | 95 (55%) | 153 (55%) | 90 (59%) | 243 (57%) |
| Male | 45 (44%) | 79 (45%) | 124 (45%) | 62 (41%) | 186 (43%) |
| Race | |||||
| White | 33 (32%) | 40 (23%) | 73 (26%) | 49 (32%) | 122 (28%) |
| Black | 37 (36%) | 62 (36%) | 99 (36%) | 42 (28%) | 141 (33%) |
| Other or unknown | 33 (32%) | 72 (41%) | 105 (38%) | 61 (40%) | 166 (39%) |
| Charlson score | 0.0 (0.0-2.0) |
1.0 (0.0-2.0) |
1.0 (0.0-2.0)† |
2.0 (1.0-4.0) |
1.0 (0.0-3.0) |
| CHA2DS2-VASc score | 3.5 (1.6) | 3.1 (1.5) | 3.3 (1.6)† | 4.1 (1.8) | 3.6 (1.7) |
| Follow-up (days) | 331.5 (181.5-577.0) |
412.9 (187.3-675.2) |
402.2 (183.3-648.4) |
293.6 (81.6-671.8) |
359.4 (159.5-654.0) |
Data are mean (SD), median (IQR), or n (%) values.
